Moderna, Inc. vs Regeneron Pharmaceuticals, Inc.: Strategic Comparison

This in-depth comparison examines Moderna, Inc. and Regeneron Pharmaceuticals, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Moderna, Inc. on its own, evaluating Regeneron Pharmaceuticals, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Moderna, Inc. and Regeneron Pharmaceuticals, Inc. is widest.

On the headline numbers, annual revenue is $1.9B (FY2025) for Moderna, Inc. and $14.3B (FY2025) for Regeneron Pharmaceuticals, Inc., while their respective market capitalizations stand at $72.7B and $75.0B. Both Moderna, Inc. and Regeneron Pharmaceuticals, Inc. are headquartered in United States. Their local markets and applicable rules may still differ.

Moderna, Inc.: Moderna, Inc. is a Nasdaq-listed biotechnology company headquartered in Cambridge, Massachusetts. It develops medicines that deliver mRNA instructions into cells so the body produces a target protein, such as a viral antigen or tumor neoantigen. As of 2026 it markets COVID-19 vaccines (Spikevax, mNEXSPIKE), an RSV vaccine (mRESVIA) and a flu vaccine (mFLUSIVA), and co-develops the individualized cancer therapy intismeran autogene with Merck.

Regeneron Pharmaceuticals, Inc.: Regeneron is a Tarrytown, New York biotech that discovers, develops and manufactures its own biologic medicines. Its best-known products are EYLEA and EYLEA HD for retinal disease, Dupixent (with Sanofi) for eczema, asthma, COPD and other Type 2 inflammatory conditions, and Libtayo for cancer. Co-founders Leonard Schleifer (CEO) and George Yancopoulos (Chief Scientific Officer) still lead the company, which had about 15,400 employees at the end of 2025. Regeneron was founded in 1988 in New York City by Dr. Leonard Schleifer and Dr. George Yancopoulos, establishing its primary laboratories in Tarrytown, New York, and pioneering the proprietary VelociSuite genetics platform to build one of the world’s most scientifically productive biopharmaceutical giants.

Moderna, Inc. and Regeneron Pharmaceuticals, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Moderna, Inc. and Regeneron Pharmaceuticals, Inc..

Moderna, Inc. business model: Moderna earns most of its revenue from net product sales of mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and from the 2026-2027 season mFLUSIVA for influenza. Buyers are governments, national immunization programs, pharmacy chains, wholesalers and health systems, so sales are concentrated in the autumn and winter vaccination season. Smaller amounts come from collaboration, licensing and grant revenue. Because every product uses the same mRNA and lipid nanoparticle backbone, Moderna can reuse manufacturing, regulatory and clinical know-how across programs, while partners such as Merck share development costs and profits on the individualized cancer vaccine intismeran autogene.

Regeneron Pharmaceuticals, Inc. business model: Regeneron makes money three ways. First, it records U.S. net product sales of its own medicines, mainly EYLEA HD and EYLEA for retinal disease, Libtayo in oncology, and smaller rare-disease products. Second, it earns collaboration revenue from Sanofi on Dupixent and Kevzara: Sanofi books global sales and the two companies share profits. Third, it shares ex-U.S. EYLEA profits with Bayer, which sells the drug outside the United States. The discovery engine behind all of this is VelociSuite, including VelocImmune mice that produce fully human antibodies.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Moderna, Inc. stack up against those of Regeneron Pharmaceuticals, Inc..

Moderna, Inc. competitive advantage: Moderna's advantages are a validated mRNA and lipid nanoparticle platform, a large patent estate on modified mRNA, in-house manufacturing in Norwood, Massachusetts plus onshore plants in the UK, Canada and Australia, and regulatory experience across approved respiratory products. The same platform produced the first FDA-approved mRNA flu vaccine (2026) and the first individualized neoantigen therapy to succeed in a Phase 3 trial.

Regeneron Pharmaceuticals, Inc. competitive advantage: Regeneron's edge is an in-house discovery platform (VelociSuite and VelocImmune) paired with the Regeneron Genetics Center's large human-sequencing dataset, which helps pick drug targets with genetic validation. Its two founders still run the company, so R&D priorities have stayed consistent for more than three decades, and it manufactures its own biologics in Rensselaer, New York and Limerick, Ireland.

Future prospects matter as much as current results. The growth strategies below explain how Moderna, Inc. and Regeneron Pharmaceuticals, Inc. each plan to expand from here.

Moderna, Inc. growth strategy: Moderna is narrowing its pipeline to programs with near-term commercial potential: respiratory vaccines (COVID, RSV, flu and combinations), individualized cancer therapy with Merck, and a small set of rare-disease and latent-virus programs. It cut R&D spending, reduced headcount below 5,000 in 2025, and is seeking expanded age and country approvals for existing vaccines while preparing filings for intismeran autogene.

Regeneron Pharmaceuticals, Inc. growth strategy: Regeneron is defending ophthalmology with EYLEA HD (8 mg aflibercept, longer dosing intervals), widening Dupixent into new Type 2 inflammatory indications such as COPD, and building oncology and hematology around Libtayo and bispecifics such as linvoseltamab and odronextamab. It is also adding modalities through gene editing with Intellia, siRNA medicines with Alnylam, gene therapy from the Decibel deal and cell therapy through Regeneron Cell Medicines.

A closer look at the financial trajectory of Moderna, Inc. and Regeneron Pharmaceuticals, Inc. rounds out the comparison.

Moderna, Inc.: Moderna went from $803 million of revenue in 2020 to $18.5 billion in 2021 and $19.3 billion in 2022, earning $12.2 billion and $8.4 billion of net income in those years. Revenue then fell to $6.8 billion in 2023, $3.2 billion in 2024 and $1.94 billion in 2025, with net losses of $4.7 billion, $3.6 billion and $2.8 billion. In 2025 Moderna cut operating expenses by about $2.2 billion (roughly 30%) and ended the year with $8.1 billion in cash and investments. Q2 2026 revenue was $145 million with a $782 million net loss; management guided to up to 10% revenue growth for 2026 and cash costs of about $4 billion. Moderna, Inc. is a major American pharmaceutical and biotechnology company pioneering messenger RNA (mRNA) therapeutics, sustaining a market valuation typically over $40 billion.

Regeneron Pharmaceuticals, Inc.: Regeneron's revenue rose from $4.86 billion in 2016 to $16.07 billion in 2021, inflated by COVID-19 antibody sales, then reset to $12.17 billion in 2022. It has since grown slowly: $13.12 billion in 2023, $14.20 billion in 2024 and $14.34 billion in 2025, as Dupixent gains offset lower original EYLEA sales. Growth picked up in 2026, with Q2 revenue up 17% to $4.3 billion, GAAP EPS of $12.23 and non-GAAP EPS of $14.29. Regeneron Pharmaceuticals, Inc. is a colossal American biotechnology company specializing in antibody therapeutics, sustaining a massive market valuation generally exceeding $100 billion.